Eosinophilic Esophagitis
Conditions
Keywords
Eosinophilic Esophagitis
Brief summary
The purpose of this study is assessing the efficacy of swallowed Flovent® vs. placebo for the treatment of eosinophilic esophagitis (EE).
Interventions
DRUGFluticasone Propionate
Flovent vs. placebo daily for 3 months
Sponsors
Marc Rothenberg
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
3 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent for study by parent or guardian. Assent will be obtained from all minors 11 years of age and older. * Age older than or equal to 3 years and younger than or equal to 30 years * Endoscopic findings consistent with EE (edema, furrowing, exudates, rings) * Histological findings to include proliferation of basal layer and peak eosinophil density ≥24 per high power field (400x). This degree of tissue eosinophilia has been shown to correlate well with poor-responsiveness to acid suppression therapy, suggesting it is a primary eosinophilic disease and not secondary to GERD\[11\]. * Allergy evaluation including skin-prick testing with multiple food antigens to insure elimination diet is not indicated. * If allergic to specific foods, option to be on a minimum 3 months of elimination diet without detectable resolution by repeat endoscopy with biopsies demonstrating no improvement to disease. * Patients enrolled at CCHMC will be under the direct care of Dr. Putnam or any of the other staff gastroenterologists at this institution who will supervise endoscopic procedures. Patients may also be enrolled at institutions other than CCHMC, but the diagnosis of EE must be validated by an expert pathologist in EE at CCHMC (Margaret Collins, MD). * 20 additional patients without EE will be enrolled as unaffected controls for purposes of comparison with patients with EE. Enrollment pool will comprise patients undergoing routine upper endoscopy and having no identifiable pathology.
Exclusion criteria
* Patients with history of poor tolerance to FP, patients unable to cooperate with use of MDI, pregnant females, patients inhaling any corticosteroid for asthma, and patients with concurrent or recent (within 3 months) use of systemic steroids.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Histologic remission | 5 years | Histologic remission,defined by a peak eosinophil count of less than/equal to 1 eosinophil in all 400 fields in both the proximal and distal esophagus. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Furrowing, Epithelial hyperplasia, clinical symptoms | 5 years | Secondary outcome measures included presence of endoscopic furrowing, presence of epithelial hyperplasia, and presence of clinical symptoms. |
Countries
United States
Outcome results
None listed